Abstract:3852 Chan su, the dried toad venom or the dried secretion from the skin glands of Bufo bufo gargarizans Cantor or B. melanotictus Schneider, has long been used as a therapeutic agent for cancer treatment in China and other Asian countries. Huachansu, an injectable form of Chan su, is a sterilized hot water extract of dried toad skin. Since 1991, huachansu has been officially approved as a regimen for treatment of cancer in China. However, the selectivity and mechanism of anti-cancer activity of huachansu have not been fully elucidated. The goals of our current study were to investigate the cytotoxicity of huachansu alone as well as the polar and non-polar compartments of huachansu and cardiac glycosides derived from huachansu against various cancer cells. In addition, we explored mechanisms associated with this extract’s antiproliferative activity. The inhibitory effects of three different lots of huachansu were tested in four different human cell lines including hepatoma (Hep 3B), colon (HT29), pancreatic (Panc-1) and melanoma (BRO) cells. The relative growth inhibitory activity on the growth of cancer cells for all three lots of huachansu was ranked as Panc-1 > HT29 > BRO > Hep3B cells. The inhibitory effect of the non-polar fraction (lipid soluble) of huachansu was much stronger than that of the polar compartment (water soluble) with IC50 of 1.75 mg /ml versus 31.25 mg (raw material)/ml, respectively. These data suggest that huachansu’s antitumor activity is mainly attributed to the lipid-soluble components. Because cardiac glycosides are one of the lipid soluble components in huachansu, we next tested the relative cytotoxicity of three different cardiac glycosides derived from huachansu, including bufalin, cinobufagin, and resibufogenin against BRO cells. The IC50 values of bufalin, cinobufagin, and resibufogenin in BRO cells were 16.7, 20.1 and 700 ng/ml, respectively. When BRO cells were treated with huachansu (1 to 25 mg/ml) for 24 hr, huachansu induced cell cycle arrest in the G2/M-phase. Furthermore, huachansu as well as bufalin down-regulated Bcl-2 expression, yet up-regulated BAX protein in BRO cells in a concentration-dependent manner. In addition, our preliminary data also demonstrated that huachansu (10 mg/ml) significantly reduced B23 (neucleophosmin), pAKT and STAT3 expression. Concomitantly, it up-regulated several cell signaling pathways such as SRC, MAPK, and Raf, which is attributed to the stress-mediated cell response of huachansu cardiac glycosides. Taken together, these results suggest that cardiac glycosides, such as bufalin, are responsible for huachansu induced cell death in BRO cells. Whether other components in huachansu also contribute to its anti-proliferative activity requires further investigation. This research was supported in part by NCI R21 CA108084-01, International Center of TCM for Cancer.

Huachansu Suppresses TRPV1 Up-Regulation and Spinal Astrocyte Activation to Prevent Oxaliplatin-Induced Peripheral Neuropathic Pain in Rats.

Huangqi Guizhi Wuwu Decoction Alleviates Oxaliplatin-Induced Peripheral Neuropathy Via the Gut-Peripheral Nerve Axis.

Huangqi Guizhi Wuwu Decoction Can Prevent and Treat Oxaliplatin Induced Neuropathic Pain by TNFα/IL-1β/IL-6/MAPK/NF-kB Pathway

Huachansu suppresses human bladder cancer cell growth through the Fas/Fasl and TNF- alpha/TNFR1 pathway in vitro and in vivo

Cinobufacini Protects Against Paclitaxel-Induced Peripheral Neuropathic Pain and Suppresses TRPV1 Up-Regulation and Spinal Astrocyte Activation in Rats.

Pilot Study of Huachansu in Patients with Hepatocellular Carcinoma, Nonsmall-Cell Lung Cancer, or Pancreatic Cancer

Puerarin suppresses TRPV1, calcitonin gene-related peptide and substance P to prevent paclitaxel-induced peripheral neuropathic pain in rats

Puerarin alleviates oxaliplatin-induced neuropathic pain by promoting Nrf2/GPX4-mediated antioxidative response

Curcumin Alleviates Oxaliplatin-Induced Peripheral Neuropathic Pain Through Inhibiting Oxidative Stress-Mediated Activation of NF-κB and Mitigating Inflammation.

Wen-Luo-Tong Prevents Glial Activation and Nociceptive Sensitization in a Rat Model of Oxaliplatin-Induced Neuropathic Pain

Modulating pancreatic cancer microenvironment: The efficacy of Huachansu in mouse models via TGF-β/Smad pathway

Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy

Huachansu injection inhibits metastasis of pancreatic cancer in mice model of human tumor xenograft

The Dual PPARα/γ Ligand TZD18 Inhibits Cell Growth and Induces Apoptosis in Human Bcr-Abl Positive CML Cell Lines >in Vitro

Pretreatment of Huaiqihuang Extractum Protects Against Cisplatin-Induced Nephrotoxicity

Huachansu, Containing Cardiac Glycosides, Enhances Radiosensitivity of Human Lung Cancer Cells.

Interpreting the Pharmacological Mechanisms of Huachansu Capsules on Hepatocellular Carcinoma Through Combining Network Pharmacology and Experimental Evaluation

Puerarin alleviates vincristine-induced neuropathic pain and neuroinflammation via inhibition of nuclear factor-κB and activation of the TGF-β/Smad pathway in rats

Sodium Aescinate Alleviates Neuropathic Pain in Rats by Suppressing the TLR4/NF KB Pathway Activation after Paclitaxel Chemotherapy

Compound-composed Chinese medicine of Huachansu triggers apoptosis of gastric cancer cells through increase of reactive oxygen species levels and suppression of proteasome activities

Anti-hypersensitivity Effects of Shu-jing-huo-xue-tang, a Chinese Herbal Medicine, in CCI-neuropathic Rats.